
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is supported by a compelling clinical and platform-driven thesis, with ABS-201 offering a differentiated anti-prolactin receptor mechanism that may produce durable hair regrowth through sustained receptor occupancy and follicular biology rather than simple cosmetic thickening. The company’s outlook is reinforced by encouraging early safety and PK data, no serious adverse events or dose-limiting toxicities, and a strong balance sheet with $173.7M in cash, cash equivalents, and marketable securities that provides runway into 2H28. Longer term, the opportunity extends beyond pattern hair loss into endometriosis, while successful validation of ABS-201 could also strengthen confidence in Absci’s AI-enabled drug discovery platform and its ability to generate proprietary, high-quality therapeutic candidates.
Bears say
Absci is a development-stage biotech with early programs and no guarantee of clinical success, while ABS-201 and other candidates face material delays from trial execution, regulatory review, competitive pressure, and reliance on third-party CDMOs. The company had $173.7M of cash, cash equivalents, and marketable securities at the end of 3Q 2026, but management only expects funding into 2H 2028 and the business is not expected to be profitable on a continuing basis until 2035. That long cash burn runway, plus the likelihood of additional capital raises and potential dilution before commercialization, makes the risk-reward profile unfavorable despite the promise of its AI-driven platform.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Absci Corp (ABSI) Forecast
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares